571186-50-0
| 中文名称 | 571186-50-0 |
|---|---|
| 中文同义词 | 化合物 T16278;化合物 NCX1022 |
| 英文名称 | 11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID |
| 英文同义词 | 11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID;NO-HYDROCORTISONE;NCX 1022;Pregn-4-ene-3,20-dione, 11,17-dihydroxy-21-[[4-[(nitrooxy)methyl]benzoyl]oxy]-, (11β)-;NCX-1022,NCX1022 |
| CAS号 | 571186-50-0 |
| 分子式 | C29H35NO9 |
| 分子量 | 541.59 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 571186-50-0.mol |
| 结构式 |  |
571186-50-0 性质
| 沸点 | 734.2±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.37±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 12.31±0.70(Predicted) |
Topical pre- and post-treatment with NCX1022 (3 nmol) in C57BL6 mice not only reduces ear oedema formation in a dose-dependent manner, but also is significantly more effective than the parent compound during the initial stages of inflammation (from 1 to 5 h). NCX1022, but not Hydrocortisone, significantly inhibits granulocyte recruitment (tissue myeloperoxidase activity). Histological samples of mouse ears treated with NCX1022 show significant reduction in both the number of infiltrated cells and disruption of the tissue architecture compared to Hydrocortisone-treated tissues. Post-treatment with Hydrocortisone does not modify the increased granulocyte infiltration induced by benzalkonium application, but NCX1022 reduces by 63% the myeloperoxidase (MPO) activity, producing a maximum effect at the dose of 3 nmol per ear. NCX1022 is significantly more potent than Hydrocortisone in reducing contact dermatitis-induced leukocyte adhesion, particularly at the early time points (e.g., 30-60 min after dermatitis induction).